Diagnostik und Therapie von Tremorsyndromen

Tremor ist die häufigste Bewegungsstörung und kann isoliert, im Rahmen von neurologischen Erkrankungen sowie im Rahmen von Erkrankungen anderer Fachgebiete oder auch als Folge von Medikamenten auftreten. Die Vielfalt der klinischen Präsentation, der Ätiologie und der Therapie macht die kontinuierliche Weiterentwicklung der klinischen diagnostischen und therapeutischen Konzepte notwendig. Dieser Beitrag stellt den aktuellen Stand der praxisbezogenen Kenntnisse und Empfehlungen vor.

Tremor is the most common movement disorder, occurring as an isolated tremor syndrome, as a symptom of neurological diseases or diseases from other medical specialty fields, or after the intake of drugs / toxins. The heterogeneous variety of the clinical presentations, the etiologies, and the therapeutical options require the continuous development of the clinical concepts in tremor disorders. This review summarizes the current state of the art of the clinical recommendations for the diagnostic and therapeutic procedures in tremor.

Schlüsselwörter

Bewegungsstörung - Tremor - Pharmakotherapie, tiefe Hirnstimulation

Key words

Movement disorder - tremor - therapy - deep brain stimulation

Publication History

Article published online:
11 December 2020

• Literatur

• 1 Bhatia KP, Bain P, Bajaj N. et al. Consensus Statement on the classification of tremors from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord 2018; 33: 75-87
• 2 Deuschl G, Bain P, Brin M. Consensus Statement of the Movement Disorder Society on Tremor. Mov Disord 1998; 13: 2-23
• 3 Deuschl G, Raethjen J, Lindemann M. et al. The pathophysiology of tremor. Muscle Nerve 2001; 24: 716-735
• 4 Elble R, Deuschl G. Milestones in Tremor Research. Mov Disord 2011; 26: 1096-105
• 5 Louis ED. The evolving definition of essential tremor: What are we dealing with?. Parkinsonism Relat Disord 2018; 46 (Suppl. 01): S87-S91
• 6 Louis ED, Ferreira JJ. How common is the most common adult movement disorder?. Update on the worldwide prevalence of essential tremor Mov Disord 2010; 25: 534-541
• 7 Clark LN, Louis ED. Essential tremor. Handb Clin Neurol 2018; 147: 229-239
• 8 Louis ED. Non-motor symptoms in essential tremor: A review of the current data and state of the field. Parkinsonism Relat Disord 2016; 22 (Suppl. 01):, S115-S118
• 9 Govert F, Becktepe JS, Deuschl G. Current concepts of essential tremor. Rev Neurol (Paris) 2016; 172: 416-422
• 10 Marin-Lahoz J, Gironell A. Linking essential tremor to the cerebellum: neurochemical evidence. Cerebellum 2016; 15: 243-252
• 11 Kuhlenbaumer G, Hopfner F, Deuschl G. Genetics of essential tremor: meta-analysis and review. Neurology 2014; 82: 1000-1007
• 12 Lavita SI, Aro R, Kiss B. et al. The role of beta-carboline alkaloids in the pathogenesis of essential tremor. Cerebellum 2016; 15: 276-84
• 13 Asenbaum S, Pirker W, Angelberger P. et al. [123I]beta-CIT and SPECT in essential tremor and Parkinsonʼs disease. J Neural Transm 1998; 105: 1213-1228
• 14 Tarakad A, Jankovic J. Essential tremor and Parkinsonʼs disease: Exploring the relationship. Tremor Other Hyperkinet Mov (N Y) 2018; 8: 589
• 15 Fekete R, Jankovic J. Revisiting the relationship between essential tremor and Parkinson’s disease. Mov Disord 2011; 26: 391-398
• 16 Deuschl G, Raethjen J, Hellriegel H. et al. Treatment of patients with essential tremor. Lancet Neurol 2011; 10: 148-161
• 17 Ferreira JJ, Mestre TA, Lyons KE. et al. MDS Evidence-based review of treatments for essential tremor. Mov Disord 2019; 34: 950-958
• 18 Bruno E, Nicoletti A, Quattrocchi G. et al. Topiramate for essential tremor. Cochrane Database Syst Rev 2017 (04) : CD009683
• 19 Bruno E, Nicoletti A, Filippini G. et al. Zonisamide for essential tremor. Cochrane Database Syst Rev 2017 (08) : CD009684
• 20 Bruno E, Nicoletti A, Quattrocchi G. et al. Alprazolam for essential tremor. Cochrane Database Syst Rev 2015 (12) : CD009681
• 21 Bruno E, Nicoletti A, Filippini G. et al. Pregabalin for essential tremor. Cochrane Database Syst Rev 2016 (10) : CD009682
• 22 Picillo M, Fasano A. Recent advances in essential tremor: surgical treatment. Parkinsonism Relat Disord 2016; 22: (Suppl. 01): S171-S175
• 23 Krack P, Martinez-Fernandez R, Del Alamo M. et al. Current applications and limitations of surgical treatments for movement disorders. Mov Disord 2017; 32: 36-52
• 24 Purrer V, Keil VC, Grotz S. et al. Magnetresonanzgesteuerter hoch fokussierter Ultraschall: eine neue Option zur Tremorbehandlung. Nervenarzt 2019; 90: 408-411
• 25 Elias WJ, Lipsman N, Ondo WG. et al. a randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med 2016; 375: 730-739
• 26 Raethjen J, Pawlas F, Lindemann M. et al. Determinants of physiologic tremor in a large normal population. Clin Neurophysiol 2000; 111: 1825-1837
• 27 Morgan J, Sethi KD. Drug-induced tremors. Lancet Neurol 2005; 4: 866-876
• 28 Köster B, Lauk M, Timmer J. et al. Central mechanisms in human enhanced physiological tremor. Neurosci Lett 1998; 241: 135-138
• 29 Jones L, Bain PG. Orthostatic tremor. Pract Neurol 2011; 11: 240-243
• 30 Hassan A, Ahlskog JE, Matsumoto JY. et al. Orthostatic tremor: Clinical, electrophysiologic, and treatment findings in 184 patients. Neurology 2016; 86: 458-464
• 31 Bain PG. Task-specific tremor. Handb Clin Neurol 2011; 100: 711-718
• 32 Soland VL, Bhatia KP. et al. Focal task-specific tremors. Mov Disord 1996; 11: 665-670
• 33 Papapetropoulos S, Singer C. Treatment of primary writing tremor with botulinum toxin type a injections: report of a case series. Clin Neuropharmacol 2006 29. 364-367
• 34 Bodranghien F, Bastian A, Casali C. et al. Consensus paper: revisiting the symptoms and signs of cerebellar syndrome. Cerebellum 2016; 15: 369-391
• 35 Munhoz RP, Picillo M, Fox SH. et al. Eligibility criteria for deep brain stimulation in parkinsonʼs disease, tremor, and dystonia. Can J Neurol Sci 2016; 43: 462-471
• 36 Fasano A, Bove F, Lang AE. The treatment of dystonic tremor: a systematic review. J Neurol Neurosurg Psychiatry 2014; 85: 759-769
• 37 Defazio G, Conte A, Gigante AF. Is tremor in dystonia a phenotypic feature of dystonia?. Neurology 2015; 84: 1053-1059
• 38 Helmich RC, Hallett M, Deuschl G. et al. Cerebral causes and consequences of Parkinsonian resting tremor: a tale of two circuits?. Brain 2012; 135: 3206-3226
• 39 S3-Leitlinie für Diagnostik und Therapie des Idiopathisches Parkinson-Syndrom. Deutsche Gesellschaft für Neurologie; Im Internet (Stand: 10.01. 2020 www.dgn.org/leitlinien/3219-030-010-idiopathisches-parkinson-syndrom
• 40 Holmes G. On certain tremors in organic cerebral lesions. Brain 1904; 27: 325-375
• 41 Raina G, Cersosimo MG, Folgar SS. et al. Holmes tremor: Clinical description, lesion localization, and treatment in a series of 29 cases. Neurology 2016; 86: 931-938
• 42 Saifee TA, Schwingenschuh P, Reilly MM. et al. Tremor in inflammatory neuropathies. J Neurol Neurosurg Psychiatry 2013; 84: 1282-1287
• 43 Deuschl G, Wilms H. Clinical spectrum and physiology of palatal tremor. Mov Disord 2002; 17 (Suppl. 02): S63-S66
• 44 Kenney C, Diamond A, Mejia N. et al. Distinguishing psychogenic and essential tremor. J Neurol Sci 2007; 263: 94-99
• 45 Schwingenschuh P, Katschnig P, Seiler S et al. Moving toward. “laboratory-supported” criteria for psychogenic tremor. Mov Disord 2011; 26: 2509-2515
• 46 Hagerman PJ, Hagerman RJ. Fragile X-associated tremor / ataxia syndrome. Ann NY Acad Sci 2015; 1338: 58-70
• 47 Jacquemont S, Hagerman RJ, Leehey M. et al. Fragile X premutation tremor / ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003; 72: 869-878
• 48 Hall DA, Berry-Kravis E, Hagerman RJ. et al. Symptomatic treatment in the fragile X-associated tremor / ataxia syndrome. Mov Disord 2006; 21: 1741-1744
• 49 Lorincz MT. Neurologic Wilson’s disease. Ann NYAcad Sci 2010; 1184: 173-187
• 50 Machado A, Chien HF, Deguti MM. et al. Neurological manifestations in Wilsonʼs disease: Report of 119 cases. Mov Disord. 2006 21. 2192-2196
• 51 Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet neurol 2015; 14: 103-113
• 52 S1-Leitlinie für Diagnostik und Therapie des Morbus Wilson. Deutsche Gesellschaft für Neurologie; Im Internet (Stand: 10.01. 2020 www.dgn.org/leitlinien/2395-ll-14-2012-morbus-wilson
• 53 Stamelou M, Charlesworth G, Cordivari C. et al. The phenotypic spectrum of DYT24 due to ANO3 mutations. Mov Disord 2014; 29: 928-934
• 54 Deutschländer AB, Wszolek ZK. DYT-GNAL. In: Adam MP, Ardinger HH, Pagon RA et al. Gene reviews. Seattle (WA), University of Washington, Seattle: 1993-2019 Im Internet (Stand 10.01 2020):. www.ncbi.nlm.nih.gov/books/NBK535640
• 55 Jochim A, Zech M, Gora-Stahlberg G. et al. The clinical phenotype of early-onset isolated dystonia caused by recessive COL6A3 mutations (DYT27). Mov Disord 2016; 31: 747-750